Drug Type Cell therapy |
Synonyms Ciliary neurotrophic factor implant Neurotech, Ciliary neurotrophic factor Neurotech, CNTF implant Neurotech + [3] |
Target |
Mechanism CNTFR agonists(Ciliary neurotrophic factor receptor agonists), Neurogenesis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationPriority Review (US) |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Start Date13 Aug 2021 |
Sponsor / Collaborator |
Start Date15 May 2021 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Macular telangiectasia type 2 | NDA/BLA | US | 20 Jun 2024 | |
Retinal Telangiectasis | Phase 3 | AU | 19 Jan 2018 | |
Retinitis Pigmentosa | Phase 3 | US | 16 Apr 2007 | |
Color Vision Defects | Phase 2 | US | 07 Jul 2012 | |
Usher Syndromes | Phase 2 | US | 20 Jan 2012 | |
Geographic Atrophy | Phase 2 | US | - | |
Glaucoma | Phase 1 | US | - | |
Glaucoma | Phase 1 | US | - | |
Optic Nerve Diseases | Phase 1 | US | - | |
Optic Nerve Diseases | Phase 1 | US | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | - | snlfxntbhp(chysvmpkqt) = arufkbmbrh zzvfaxfoqi (rkeaqxnqto ) | - | 23 Apr 2023 | ||
Phase 3 | 115 | lvfkuihzdv(auwucwxcao) = bumrgvsaru rsdowcwuhh (uxpupzcbqz ) | Positive | 02 Nov 2022 | |||
Sham Procedure | - | ||||||
Biospace Manual | Phase 3 | 113 | rgrtocytnc(qlwejjnkxr) = wkjooiscqe zbqycogwtl (qehhzcwuta ) View more | Positive | 02 Nov 2022 | ||
Sham Procedure | - | ||||||
Phase 3 | - | sznilypeon(kkbmyzrymi) = athgqdkgde ujvvmlppju (ghntyuayuo, 0.19) | Positive | 15 Mar 2021 | |||
untreated | sznilypeon(kkbmyzrymi) = aufzmomezr ujvvmlppju (ghntyuayuo, 0.11) |